We used a γδ TCR neutralizing antibody that, rather than depleting γδ T cells, blocks signaling via the γδ TCR.10 27 We tested the effect of this antibody compared with the isotype control in WT versus IL-38 KO PyMT mice, from week 13 onwards for 5 weeks (figure 4A), when differences concerning tumor growth between WT versus KO tumors were not yet apparent (figure 1A). This evidence concerns the gene IL1F10 and neoplasm.